ALB and neoplasm: Additionally, albumin nanoparticles that are modified with mannose and encapsulated with drugs such as regorafenib, target albumin-binding proteins such as secreted protein acidic and rich in cysteine (SPARC) overexpressed in tumor cells and the protumor TAM2, serving both as a delivery and therapeutic strategy.